Universitaet Leipzig
Universitaet Leipzig is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
Proof-of-Concept Evaluation of Immunological Assays Using Human Blood and Urine Samples after Vaccination with StroVac
Sponsor Strathmann GmbH & Co. KG
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metastatic esophagogastric adenocarcinoma
Sponsor Institut fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (MDS)
Sponsor GCP-Service International West GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS or oligoblastic AML
Sponsor GWT-Tud GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
Sponsor Universitaetsklinikum Tuebingen AöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase II study of standard of care therapy azacitidine (AZA) combined with venetoclax (VEN) and Tagraxofusp (TAG) in patients with higher-Risk chronic myelomonocytic Leukemia (CMML): the PATROL Study
Sponsor GCP-Service International West GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis
Sponsor Cellerys AG
- Start (EU)
- Latest update
- Estimated end
NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)
Sponsor GWT-Tud GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Universitaet Leipzig?
The 2026-10-09 snapshot links Universitaet Leipzig to 11 distinct CTIS trials. Recorded services include Laboratory services, Data management, Safety reporting & pharmacovigilance, Statistical analysis, among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitaet Leipzig?
The most frequently recorded therapeutic areas are Haematological Malignancies, Infectious Disease, Urology. Recorded phases include Phase 2, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitaet Leipzig conducted?
The linked trials record locations in 9 countries, including Germany, Austria, Spain, Italy, France. These are trial locations, not confirmed office locations or countries where Universitaet Leipzig delivered services.
What can this page tell me about Universitaet Leipzig's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitaet Leipzig. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitaet Leipzig